Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 54, Issue -, Pages 1-10Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2020.06.004
Keywords
-
Categories
Funding
- Science and Technology Development Fund, Macau SAR [0096/2018/A3, 130/2017/A3, 0099/2018/A3]
- NSFC overseas and Hong Kong and Macao Scholars Cooperative Research Fund Project [81828013]
Ask authors/readers for more resources
Immune checkpoint blockade therapies that target CTLA-4 and PD-1/PD-L1 have ushered in a new era of cancer treatment. Nevertheless, a significant proportion of patients demonstrated primary or acquired resistance. Harnessing gut microbiota has been an emerging novel therapeutic strategy to overcome resistance. Here we summarized the current research status of gut microbiota inimmunecheckpoint blockadetherapies, clinical trials, underlying mechanisms and challenges of microbiome research in checkpoint immunotherapy. Findings from preclinical models, standardized microbiome analysis and progress of multi-omic approaches may better disclose the interaction between gut microbiota and immune checkpoint inhibitors (ICIs) and traditional Chinese medicine can be a potential microbiome modulator to sensitize the response to ICIs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available